表紙
市場調查報告書
商品編碼
1020239

生物相似藥的全球市場:2021年∼2025年

Global Biosimilars Market 2021-2025

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球生物相似藥的市場規模在2021年∼2025年間,預測將成長到314億美元,在預測期間中預計將以24.77%的年複合成長率增長。

市場成長的主要因素有生物仿製藥相對於生物製藥的價格優勢以及主要生物製藥專利的到期。

本報告涵括生物相似藥的全球市場的整體分析,提供市場規模與預測,趨勢,成長要素,課題,及約25供應商的分析。

目錄

摘要整理

市場形勢

  • 市場生態系統
  • 價值鏈分析

市場規模

  • 市場定義
  • 市場區隔分析
  • 2020年的市場規模
  • 市場預測:從2020年∼2025年的預測

波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入廠商業者的威脅
  • 替代品的威脅
  • 競爭的威脅
  • 市場情況

市場區隔:各應用領域

  • 市場區隔
  • 各應用領域比較
  • 腫瘤學·血液學:市場規模與預測(2020年∼2025年)
  • 免疫學:市場規模與預測(2020年∼2025年)
  • 內分泌學:市場規模與預測(2020年∼2025年)
  • 腎臟學:市場規模與預測(2020年∼2025年)
  • 各應用領域的市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 歐洲:市場規模與預測(2020年∼2025年)
  • 亞洲:市場規模與預測(2020年∼2025年)
  • 北美:市場規模與預測(2020年∼2025年)
  • 其他地區:市場規模與預測(2020年∼2025年)
  • 主要國家
  • 地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 業者情勢
  • 創造性破壞狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Amgen Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Viatris Inc.

附錄

目錄
Product Code: IRTNTR70710

Technavio has been monitoring the biosimilars market and it is poised to grow by $ 31.40 bn during 2021-2025, progressing at a CAGR of 24.77% during the forecast period. Our report on the biosimilars market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by factors such as the price advantage of biosimilars over biologics and the patent expiry of major biologics. In addition, the price advantage of biosimilars over biologics is anticipated to boost the growth of the market as well.

The biosimilars market analysis includes the application segment and geographic landscape.

Technavio's biosimilars market is segmented as below:

By Application

  • Oncology and hematology
  • Immunology
  • Endocrinology
  • Nephrology

By Geography

  • Europe
  • Asia
  • North America
  • ROW

This study identifies the government initiatives to increase the use of biosimilar medicines as one of the prime reasons driving the biosimilars market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on biosimilars market covers the following areas:

  • Biosimilars market sizing
  • Biosimilars market forecast
  • Biosimilars market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biosimilars market vendors that include Amgen Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Merck and Co. Inc., Novartis AG, Pfizer Inc., and Viatris Inc. Also, the biosimilars market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market Overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Application
    • Market segments
    • Comparison by Application
    • Oncology and hematology - Market size and forecast 2020-2025
    • Immunology - Market size and forecast 2020-2025
    • Endocrinology - Market size and forecast 2020-2025
    • Nephrology - Market size and forecast 2020-2025
    • Market opportunity by Application
  • Customer landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • North America - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Overview
    • Vendor landscape
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • Amgen Inc.
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • Eli Lilly and Co.
    • F. Hoffmann-La Roche Ltd.
    • Fresenius Kabi AG
    • Merck and Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Viatris Inc.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Exhibits

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ billion)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Application - Market share 2020-2025 (%)
  • 22: Comparison by Application
  • 23: Oncology and hematology - Market size and forecast 2020-2025 ($ billion)
  • 24: Oncology and hematology - Year-over-year growth 2020-2025 (%)
  • 25: Immunology - Market size and forecast 2020-2025 ($ billion)
  • 26: Immunology - Year-over-year growth 2020-2025 (%)
  • 27: Endocrinology - Market size and forecast 2020-2025 ($ billion)
  • 28: Endocrinology - Year-over-year growth 2020-2025 (%)
  • 29: Nephrology - Market size and forecast 2020-2025 ($ billion)
  • 30: Nephrology - Year-over-year growth 2020-2025 (%)
  • 31: Market opportunity by Application
  • 32: Customer landscape
  • 33: Market share by geography 2020-2025 (%)
  • 34: Geographic comparison
  • 35: Europe - Market size and forecast 2020-2025 ($ billion)
  • 36: Europe - Year-over-year growth 2020-2025 (%)
  • 37: Asia - Market size and forecast 2020-2025 ($ billion)
  • 38: Asia - Year-over-year growth 2020-2025 (%)
  • 39: North America - Market size and forecast 2020-2025 ($ billion)
  • 40: North America - Year-over-year growth 2020-2025 (%)
  • 41: ROW - Market size and forecast 2020-2025 ($ billion)
  • 42: ROW - Year-over-year growth 2020-2025 (%)
  • 43: Key leading countries
  • 44: Market opportunity by geography ($ billion)
  • 45: Impact of drivers and challenges
  • 46: Vendor landscape
  • 47: Landscape disruption
  • 48: Industry risks
  • 49: Vendors covered
  • 50: Market positioning of vendors
  • 51: Amgen Inc. - Overview
  • 52: Amgen Inc. - Business segments
  • 53: Amgen Inc. - Key offerings
  • 54: Amgen Inc. - Key customers
  • 55: Amgen Inc. - Segment focus
  • 56: Biogen Inc. - Overview
  • 57: Biogen Inc. - Business segments
  • 58: Biogen Inc. - Key offerings
  • 59: Biogen Inc. - Key customers
  • 60: Biogen Inc. - Segment focus
  • 61: Boehringer Ingelheim International GmbH - Overview
  • 62: Boehringer Ingelheim International GmbH - Business segments
  • 63: Boehringer Ingelheim International GmbH - Key offerings
  • 64: Boehringer Ingelheim International GmbH - Key customers
  • 65: Boehringer Ingelheim International GmbH - Segment focus
  • 66: Eli Lilly and Co. - Overview
  • 67: Eli Lilly and Co. - Business segments
  • 68: Eli Lilly and Co. - Key offerings
  • 69: Eli Lilly and Co. - Key customers
  • 70: Eli Lilly and Co. - Segment focus
  • 71: F. Hoffmann-La Roche Ltd. - Overview
  • 72: F. Hoffmann-La Roche Ltd. - Business segments
  • 73: F. Hoffmann-La Roche Ltd. - Key offerings
  • 74: F. Hoffmann-La Roche Ltd. - Key customers
  • 75: F. Hoffmann-La Roche Ltd. - Segment focus
  • 76: Fresenius Kabi AG - Overview
  • 77: Fresenius Kabi AG - Business segments
  • 78: Fresenius Kabi AG - Key offerings
  • 79: Fresenius Kabi AG - Key customers
  • 80: Fresenius Kabi AG - Segment focus
  • 81: Merck and Co. Inc. - Overview
  • 82: Merck and Co. Inc. - Business segments
  • 83: Merck and Co. Inc. - Key offerings
  • 84: Merck and Co. Inc. - Key customers
  • 85: Merck and Co. Inc. - Segment focus
  • 86: Novartis AG - Overview
  • 87: Novartis AG - Business segments
  • 88: Novartis AG - Key offerings
  • 89: Novartis AG - Key customers
  • 90: Novartis AG - Segment focus
  • 91: Pfizer Inc. - Overview
  • 92: Pfizer Inc. - Business segments
  • 93: Pfizer Inc. - Key offerings
  • 94: Pfizer Inc. - Key customers
  • 95: Pfizer Inc. - Segment focus
  • 96: Viatris Inc. - Overview
  • 97: Viatris Inc. - Business segments
  • 98: Viatris Inc. - Key offerings
  • 99: Viatris Inc. - Key customers
  • 100: Viatris Inc. - Segment focus
  • 101: Currency conversion rates for US$
  • 102: Research Methodology
  • 103: Validation techniques employed for market sizing
  • 104: Information sources
  • 105: List of abbreviations